Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Basilea Reports That Ceftobiprole Received QIDP Designation From U.S. FDA for the Treatment of Staph

https://www.biospace.com/article/releases/basilea-December 22, 2017

Tag: Cefuroxime , SAB

PharmaSources Customer Service